GlassScriptPhysician profile
Mohammad S Siddiqui
NPI 1487742383
$5,722.84
in general payments reported to CMS, 2019-2025
32 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $1,001 · 2021: $717 · 2022: $265 · 2023: $575 · 2024: $769 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $935.59 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $784.53 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $656.93 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.46 | 2019-2025 | Jascayd, Ofev |
| Glaxosmithkline, LLC. | $463.11 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $349.09 | 2019-2025 | Winrevair |
| Philips North America LLC | $323.57 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $246.61 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $212.31 | 2022-2025 | Dupixent |
| Inspire Medical Systems, INC. | $150.67 | 2023-2025 | Inspire |
| Verona Pharma, INC. | $146.74 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $131.95 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $125.59 | 2020-2021 | |
| Baxter Healthcare | $89.94 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $80.55 | 2021-2025 | Arikayce |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $78.57 | 2019 | |
| Viatris Specialty LLC | $58.96 | 2025 | Yupelri |
| Amgen INC. | $43.77 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.74 | 2020-2021 | |
| Pulmonx Corporation | $42.32 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Pfizer INC. | $36.65 | 2022-2024 | |
| Inogen, INC. | $36.41 | 2020-2024 | |
| Astellas Pharma US INC | $32.65 | 2024 | Izervay |
| Circassia INC. | $31.15 | 2019 | |
| United Therapeutics Corporation | $25.50 | 2019 | |
| Smith+Nephew, INC. | $24.25 | 2025 | Renasys Touch |
| Abbvie INC. | $20.67 | 2023 | Avycaz |
| Mannkind Corporation | $19.70 | 2025 | |
| Electromed, INC. | $18.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.16 | 2019 | |
| Genentech USA, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.